{"DataElement":{"publicId":"6824989","version":"1","preferredName":"Tumor Lysis Syndrome Initiation Therapy Present  Status","preferredDefinition":"A condition or state at a particular time related to the presence of Tumor Lysis Syndrome at the initiation of treatment.","longName":"TLS_INT_THPY_PRES_STAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6824986","version":"1","preferredName":"Tumor Lysis Syndrome Initiation Therapeutic Procedure Present","preferredDefinition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death._The act of starting something; an act that sets in motion some course of events._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Being or existing in a specified place or at the specified time.","longName":"6824983v1.0:6824984v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"6824983","version":"1","preferredName":"Tumor Lysis Syndrome","preferredDefinition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.","longName":"C3425","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Lysis Syndrome","conceptCode":"C3425","definition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6BFF69-94C5-6C92-E053-F662850A4747","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6824984","version":"1","preferredName":"Initiation Therapeutic Procedure Present","preferredDefinition":"The act of starting something; an act that sets in motion some course of events.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Being or existing in a specified place or at the specified time.","longName":"C47938:C49236:C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initiation","conceptCode":"C47938","definition":"The act of starting something; an act that sets in motion some course of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6BFF69-94D7-6C92-E053-F662850A4747","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6BFF69-94E8-6C92-E053-F662850A4747","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"SOKKERL","dateModified":"2019-07-24","changeDescription":"7/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6824988","version":"1","preferredName":"Tumor Lysis Syndrome Status","preferredDefinition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death._A condition or state at a particular time.","longName":"6824988v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E707256-D63A-346E-E053-F662850A18D3","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Absence","valueDescription":"Absent","ValueMeaning":{"publicId":"2562943","version":"1","preferredName":"Absent","longName":"2562943","preferredDefinition":"Not existing in a specified place at a specified time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Absent","conceptCode":"C48190","definition":"Not existing in a specified place at a specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C2EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"REEVESD","dateModified":"2014-11-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6E4BB9-7906-3263-E053-F662850A993E","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Presence","valueDescription":"Present","ValueMeaning":{"publicId":"2562862","version":"1","preferredName":"Present","longName":"2562862","preferredDefinition":"Being or existing in a specified place or at the specified time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C29B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"COOPERM","dateModified":"2018-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6E4BB9-7910-3263-E053-F662850A993E","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6824987","version":"1","preferredName":"Tumor Lysis Syndrome Status","preferredDefinition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.:A condition or state at a particular time.","longName":"C3425:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Lysis Syndrome","conceptCode":"C3425","definition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6E4BB9-78CA-3263-E053-F662850A993E","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6E4BB9-78DB-3263-E053-F662850A993E","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"SOKKERL","dateModified":"2019-07-24","changeDescription":"7/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Was Tumor Lysis syndrome pres","type":"Preferred Question Text","description":"Was Tumor Lysis syndrome present at initiation of treatment","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6ED1D0-C4DE-7ACA-E053-F662850AEC02","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"SOKKERL","dateModified":"2019-07-24","changeDescription":"7/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}